The global coronary heart disease diagnostic imaging devices market is expected to reach USD 2.96 billion by 2030, registering a CAGR of 6.9% from 2022 to 2030. Increase in coronary diseases and deaths associated with it calls for better and early diagnosis of the condition. Precise scan interpretation and technologically advanced equipment are the factors influencing the market growth. Various imaging modalities are useful in identifying unique aspects of coronary screening. For instance, intravascular ultrasound, X-ray angiography, and computed tomography angiography (CTCA) provide a direct evaluation and quantification of alterations in the coronary arteries. However, non-invasive techniques like single-photon computed tomography (SPECT) and positron emission tomography (PET) provide indirect information on CHD by estimating the myocardial perfusion and metabolism abnormalities that are consequent of coronary artery disease.
Technological advancement in this field had led to the development of sharp camera units consisting of gamma systems, that use semiconductor detectors of cadmium zinc telluride (CZT). This led to faster acquisition of images, reduced capture time, high image quality, and lower radiation dose (1mSv for a single injection), as compared to conventional myocardial perfusion imaging by SPECT. Further, improvements around Computed Tomography, to develop non-invasive techniques have also shown great future growth in this segment. However, economic barriers, subject literacy, and lack of medical staff hold back the implementation of such advanced techniques in real practice.
The coronary heart disease diagnostic imaging devices market saw a sharp decline in 2020, due to the outbreak of the COVID-19 pandemic. Fear of virus spread, the shift in focus on diagnosing and treating COVID-19 affected patients, reduced admission rates at hospitals for other diseases, and reduced medical staff, led to the reduction in the diagnosis of CVD. Economic setback observed by end-users also influenced the adoption of advanced techniques to effectively diagnoses coronary alterations. Further, the shutting down of manufacturing units, due to national lockdowns, halt in logistics, and reduction in salesforce also impacted the market negatively. However, diabetic and hypertensive patients witnessed a severe risk of CVD ultimately leading to death. Thus, the pandemic significantly impacted the market in 2020, which is likely to stabilize and grow exponentially by 2022.
This product will be delivered within 1-3 business days.
Technological advancement in this field had led to the development of sharp camera units consisting of gamma systems, that use semiconductor detectors of cadmium zinc telluride (CZT). This led to faster acquisition of images, reduced capture time, high image quality, and lower radiation dose (1mSv for a single injection), as compared to conventional myocardial perfusion imaging by SPECT. Further, improvements around Computed Tomography, to develop non-invasive techniques have also shown great future growth in this segment. However, economic barriers, subject literacy, and lack of medical staff hold back the implementation of such advanced techniques in real practice.
The coronary heart disease diagnostic imaging devices market saw a sharp decline in 2020, due to the outbreak of the COVID-19 pandemic. Fear of virus spread, the shift in focus on diagnosing and treating COVID-19 affected patients, reduced admission rates at hospitals for other diseases, and reduced medical staff, led to the reduction in the diagnosis of CVD. Economic setback observed by end-users also influenced the adoption of advanced techniques to effectively diagnoses coronary alterations. Further, the shutting down of manufacturing units, due to national lockdowns, halt in logistics, and reduction in salesforce also impacted the market negatively. However, diabetic and hypertensive patients witnessed a severe risk of CVD ultimately leading to death. Thus, the pandemic significantly impacted the market in 2020, which is likely to stabilize and grow exponentially by 2022.
Coronary Heart Disease Imaging Devices Market Report Highlights
- Nuclear medicine dominated the modality segment due to the ease of image interpretation and accuracy in detection.
- Computed tomography held the highest CAGR of 7.6% due to its advantages of early detection of even the most intricate alterations which otherwise is impossible to det4ect in the traditional SPECT technology.
- Asia Pacific is anticipated to be growing at the fastest CAGR over the forecast period owing to the increase in R&D activities and numerous resellers.
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Coronary Heart Disease Diagnostic Imaging Devices Market Variables, Trends & Scope
Chapter 4. Coronary Heart Disease Diagnostic Imaging Devices Market: Modality Estimates & Trend Analysis
Chapter 5. Coronary Heart Disease Diagnostic Imaging Devices Market: Regional Estimates & Trend Analysis
Chapter 6. Competitive Landscape
Companies Mentioned
- GE Healthcare
- Fujifilm
- Siemens Healthineer
- Toshiba
- Hitachi
- Koninklijke Phillips
- Canon Medical Systems Corporation
- Analogic Corporation
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 120 |
| Published | April 2022 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 1.73 Billion |
| Forecasted Market Value ( USD | $ 2.96 Billion |
| Compound Annual Growth Rate | 6.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 8 |
